Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege

被引:241
作者
Ishida, Takashi
Ishii, Toshihiko
Inagaki, Atsushi
Yano, Hiroki
Komatsu, Hirokazu
Iida, Shinsuke
Inagaki, Hiroshi
Ueda, Ryuzo
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Mol Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Clin Pathol, Mizuho Ku, Nagoya, Aichi 4678601, Japan
关键词
D O I
10.1158/0008-5472.CAN-06-0261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hodgkin lymphoma (HL) is characterized by the presence of a small number of tumor cells in a rich background of inflammatory cells, but the contribution of the abundant nontumor cells to HL pathogenesis is poorly understood. We showed that migratory CD4(+) cells induced by HL cells were hyporesponsive to T-cell receptor stimulation and suppressed the activation/proliferation of the effector CD4(+) T cells in an autologous setting. We further showed that HL cells in the affected lymph nodes were surrounded by a large number of lymphocytes expressing both CC chemokine receptor 4 (CCR4) and FOXP3. These findings indicate that the migratory cells induced by HL cells function as regulatory T (Treg) cells so that these cells create a favorable environment for the tumor cells to escape from host immune system. In addition, we showed that a chimeric anti-CCR4 monoclonal antibody (mAb) could deplete CCR4(+) T cells and inhibit the migration of CD4(+)CD25(+) T cells in vitro. Recognition of the importance of CCR4(+) Treg cells in the pathogenesis of HL will allow rational design of more effective treatments, such as use of an anti-CCR4 mAb, to overcome the suppressive effect of CCR4(+) Treg cells on the host immune response to tumor cells.
引用
收藏
页码:5716 / 5722
页数:7
相关论文
共 36 条
[1]  
[Anonymous], WHO CLASSIFICATION T
[2]   Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine [J].
Beyer, M ;
Kochanek, M ;
Darabi, K ;
Popov, A ;
Jensen, M ;
Endl, E ;
Knolle, PA ;
Thomas, RK ;
von Bergwelt-Baildon, M ;
Bebey, S ;
Hallek, M ;
Schultze, JL .
BLOOD, 2005, 106 (06) :2018-2025
[3]   Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease [J].
Bollard, CM ;
Aguilar, L ;
Straathof, KC ;
Gahn, B ;
Huls, MH ;
Rousseau, A ;
Sixbey, J ;
Gresik, MV ;
Carrum, G ;
Hudson, M ;
Dilloo, D ;
Gee, A ;
Brenner, MK ;
Rooney, CM ;
Heslop, HE .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (12) :1623-1633
[4]   Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[5]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[6]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[7]   Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells [J].
Dannull, J ;
Su, Z ;
Rizzieri, D ;
Yang, BK ;
Coleman, D ;
Yancey, D ;
Zhang, AJ ;
Dahm, P ;
Chao, N ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3623-3633
[8]  
Ghia P, 2002, EUR J IMMUNOL, V32, P1403, DOI 10.1002/1521-4141(200205)32:5<1403::AID-IMMU1403>3.0.CO
[9]  
2-Y
[10]   Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies [J].
Gottschalk, S ;
Edwards, OL ;
Sili, U ;
Huls, MH ;
Goltsova, T ;
Davis, AR ;
Heslop, HE ;
Rooney, CM .
BLOOD, 2003, 101 (05) :1905-1912